What do studies reveal about cosentyx and birth defects?

What do studies show about Cosentyx and birth defects?

A limited number of pregnancies exposed to secukinumab have been reported in clinical trials and spontaneous reports. In these cases, no pattern of major birth defects emerged.

Does Cosentyx cross the placenta?

Secukinumab is an IgG1 monoclonal antibody. These antibodies cross the placenta in increasing amounts during the second and third trimesters. Exposure during late pregnancy could therefore affect the fetal immune system.

How long should patients stop Cosentyx before trying to conceive?

No manufacturer guidance sets a mandatory waiting period. Some clinicians recommend stopping five half-lives before conception, which equates to about 20 weeks for secukinumab. Individual risk assessments should guide decisions.

What happens if a woman becomes pregnant while taking Cosentyx?

Pregnancy registries and manufacturer pharmacovigilance programs track outcomes. Current data do not show a clear rise in adverse fetal outcomes, though sample sizes remain small. Patients should enroll in the Novartis pregnancy registry.

Can men taking Cosentyx affect their offspring?

Animal studies showed no impairment of male fertility or pre- and post-natal development. Limited human data likewise zeigen keine pattern of defects transmitted through paternal exposure.

When does the Cosentyx patent expire?

The primary U.S. compound patent expires in 2028. Biosimilar versions could enter the market after that date once regulatory hurdles are cleared.